The goal of this preclinical program is to develop efficacious regimens for the clinical prevention of cancer.
Current efforts focus on the chemoprevention of colon, lung and oral cancer.
Previous studies in both mice with colitis-associated colon cancer and individuals at increased risk for colorectal cancer have revealed an association between Phase II detoxication enzyme deficiencies and increased susceptibility for cancer. The contribution of polymorphisms in Phase I and II detoxication enzymes to cancer risk is currently being examined by characterizing populations known to be at high risk and generating genetically defined mouse models. The ability of oltipraz to inhibit colitis-associated colon cancer and pancreatic cancer has been demonstrated. The molecular basis for this chemopreventive activity remains an area of active investigation. Recent Publications Clapper, M.L. Genetic polymorphisms and cancer risk.